生产企业：Encoded Therapeutics
ETX101 is an investigational AAV9-based gene regulation gene therapy developed by Encoded Therapeutics for SCN1A+ Dravet syndrome. Interim Phase 1/2 POLARIS data showed substantial and durable reductions in monthly countable seizure frequency after a single administration, along with progressive gains in cognitive and adaptive behavior measures.
ETX101 is an investigational AAV9-based gene regulation gene therapy developed by Encoded Therapeutics for SCN1A+ Dravet syndrome. Interim Phase 1/2 POLARIS data showed substantial and durable reductions in monthly countable seizure frequency after a single administration, along with progressive gains in cognitive and adaptive behavior measures.
共 1 项相关疾病
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
